Evaluation of SAMP8 Mice As a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant
Overview
Neurology
Authors
Affiliations
Background: Many patients with Alzheimer's disease (AD) display circadian rhythm and sleep-wake disturbances. However, few mouse AD models exhibit these disturbances. Lemborexant, a dual orexin receptor antagonist, is under development for treating circadian rhythm disorders in dementia.
Objective: Evaluation of senescence-accelerated mouse prone-8 (SAMP8) mice as a model for sleep-wake and rhythm disturbances in AD and the effect of lemborexant by assessing sleep-wake/diurnal rhythm behavior.
Methods: SAMP8 and control senescence-accelerated mouse resistant-1 (SAMR1) mice received vehicle or lemborexant at light onset; plasma lemborexant and diurnal cerebrospinal fluid (CSF) orexin concentrations were assessed. Sleep-wake behavior and running wheel activity were evaluated.
Results: Plasma lemborexant concentrations were similar between strains. The peak/nadir timing of CSF orexin concentrations were approximately opposite between strains. During lights-on, SAMP8 mice showed less non-rapid eye movement (non-REM) and REM sleep than SAMR1 mice. Lemborexant treatment normalized wakefulness/non-REM sleep in SAMP8 mice. During lights-off, lemborexant-treated SAMR1 mice showed increased non-REM sleep; lemborexant-treated SAMP8 mice displayed increased wakefulness. SAMP8 mice showed differences in electroencephalogram architecture versus SAMR1 mice. SAMP8 mice exhibited more running wheel activity during lights-on. Lemborexant treatment reduced activity during lights-on and increased activity in the latter half of lights-off, demonstrating a corrective effect on overall diurnal rhythm. Lemborexant delayed the acrophase of activity in both strains by approximately 1 hour.
Conclusion: SAMP8 mice display several aspects of sleep-wake and rhythm disturbances in AD, notably mistimed activity. These findings provide some preclinical rationale for evaluating lemborexant in patients with AD who experience sleep-wake and rhythm disturbances.
Wu Y, Liu R, Wei C, Wang X, Wu X, Li Y Nutrients. 2024; 16(22).
PMID: 39599637 PMC: 11597617. DOI: 10.3390/nu16223851.
Circadian rhythm disruption and retinal dysfunction: a bidirectional link in Alzheimer's disease?.
Carrero L, Antequera D, Municio C, Carro E Neural Regen Res. 2024; 19(9):1967-1972.
PMID: 38227523 PMC: 11040320. DOI: 10.4103/1673-5374.390962.
Chen Q, Liu R, Wei C, Wang X, Wu X, Fan R Nutrients. 2023; 15(24).
PMID: 38140389 PMC: 10745527. DOI: 10.3390/nu15245130.
Yin J, Tuo C, Yu K, Hu X, Fan Y, Wu M Neuromolecular Med. 2023; 25(4):632-643.
PMID: 37843792 DOI: 10.1007/s12017-023-08767-w.
Progressive sleep disturbance in various transgenic mouse models of Alzheimer's disease.
Drew V, Wang C, Kim T Front Aging Neurosci. 2023; 15:1119810.
PMID: 37273656 PMC: 10235623. DOI: 10.3389/fnagi.2023.1119810.